There are 2789 resources available
823TiP - Fluzoparide combined with apatinib mesylate in the treatment of platinum resistant recurrent ovarian cancer: A single arm, single center, prospective clinical study
Presenter: Li xin Sun
Session: ePoster Display
824TiP - An open-label, single arm, phase II trial of niraparib in combination with anti-PD1 antibody in recurrent/advanced stage endometrial cancer patients
Presenter: Jundong Li
Session: ePoster Display
Resources:
Abstract
834P - Role of assessment of IL-6, IL-15 and soluble PD-L1 levels as prognostic and predictive biomarkers in nivolumab-treated relapsed/refractory Hodgkin lymphoma
Presenter: Andrey Chekalov
Session: ePoster Display
835P - Enhancement of the International Prognostic Index with hematologic parameters: A new prognostic model for diffuse large B-cell lymphoma treated with R-CHOP
Presenter: Haizhu Chen
Session: ePoster Display
836P - Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: A Hong Kong population-based study
Presenter: Shing Fung Lee
Session: ePoster Display
976P - The 30-day mortality rate after first cycle of immunotherapy
Presenter: Osman Sutcuoglu
Session: ePoster Display
977P - Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
Presenter: Keun-Wook Lee
Session: ePoster Display
979P - Efficacy of pembrolizumab with concomitant use of antibiotics
Presenter: Katharine Ng
Session: ePoster Display
980P - Phase Ib study of a liposomal formulation of eribulin (E7389-LF) + nivolumab (Nivo) in patients (pts) with advanced solid tumors
Presenter: Noboru Yamamoto
Session: ePoster Display